Lv3
300 积分 2024-03-07 加入
Prognostic performance of the 2023 FIGO staging schema for endometrial cancer
2天前
已完结
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records
3天前
已完结
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer
4天前
已完结
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
4天前
已完结
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
4天前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
4天前
已完结
Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study
4天前
已关闭
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
5天前
已完结
Prognostic Significance of Size, Location, and Number of Lymph Node Metastases in Endometrial Carcinoma
5天前
已完结
The role and participation of immune cells in the endometrial tumor microenvironment
8天前
已完结
皖公网安备34019202002308
